WHO ICTRP trial
Phase II trial using imatinib combined with chemotherapy for newly diagnosed…
JPRN-UMIN000001226 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000001226 |
|---|---|
| Public title | Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) |
| Scientific title | Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) - Phase II trial using imatinib combined with chemotherapy for Ph+ALL |
| Primary sponsor | Japan Adult Leukemia Study Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) |
| Interventions | Induction CPM 1.2 g/m2 (*800 mg/m2) day 1 DNR 60 mg/m2 (*30 mg/m2) day 1-3 VCR 1.3 mg/m2 (max 2 mg)day 1,8,15,22 PSL 60 mg/m2 PO on day 1-21 (*7) tapered Imatinib 600 mg/body/day on day 8-42 MTX 15 mg + Ara-C 40 mg + DEX 4 mg/body IT on day… |
| Registration date | Jul 7, 2008 |
| Target size | 66 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: